Summary: Serum alanine aminotransferase, aspartate aminotransferase and -glutamyltransferase activities were monitored in psychiatric patients receiving normal doses of phenothiazine neuroleptics over a 30-day period. The first two enzymes showed slight initial increases and a subsequent return to normal, while the third showed a slight increase. In rats, dosage levels exceeding those used in human therapy produced much larger increases in the catalytic concentrations of all three enzymes in serum (1.4, 0.7 and 0.5 above the control value, respectively), and somewhat smaller increases in the liver homogenates of these animals.
Introducrion
should be reflected by catalytic activities in Most types of neuroleptic drugs presently available serum. Increases of serum creatine kinase, aspartate are known to produce unwanted side effects, some aminotransferase, alanine aminotransferase, and alof them adverse, thereby greatly impairing the useful-kaline phosphatase have actually been reported (3, 4 , ness of these drugs. The side effects may be neurologi-5). The mechanisms of action of phenothiazines in cal, endbcrinological, allergic and biochemical (1) . In the source organ of serum enzymes, namely the liver, the particular, the phenothiazine neuroleptics, pro-are not completely understood. It is assumed that mazine and chloropromazine, reportedly cause aplas-these agents cause a swelling of liver tissue. As a tic anaemia, agranulocytosis and thrombocytopenia consequence the canaliculi are compressed and the in some patients (2) . At the same time the catalytic bile flow is reduced (6) , but the effect might extend activity of enzymes might become affected, and these äs far äs cellular disruption.
Neuroleptic phenothiazines lacking the chlorine atom are generally considered to be less toxic than their developmental predecessors. To check this claim we examined the effects of chlorine-free phenothiazines on alanine aminotransferase (L-.alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2), aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1) and γ-glutamyltransferase (γ-glutamyl peptide: aminoacyl glutamyltransferase, EC 2.3.2.2) in patients treated with these drugs. The effects of doses higher than the therapeutic level were examined in animal experiments.
Methods
Alanine aminotransferase and aspartate aminotransferase activities were determined according to the methods of Schmidt & Schmidt (7) . γ-Ghitamyltransferase activities were determined according to the method of Szasz (8) . An LKB 2086 MARK analyser was used for the alanine aminotransferase and aspartate aminotransferase determinations, spectrophotometric measurements of γ-glutamyltransferase were made with a Perkin-Elmer Model 139 UWIS spectrophotometer.
Total protein concentrations in the supernatants of liver homogenates were determined according to Lowry at al. (9) .
The Wilcoxon (10) statistical treatment was used in evaluating the animal experiments.
Materials and Methods

Treatment and sampling, patients
The sera were obtained from male psychiatric patients newly admitted to the ward showing no pathologic Symptoms of the liver. Patients were immediately subjected to 30-day treatment with daily doses of Individual doses applied intramuscularly were sized in accordance with the severity of the case. Blood was collected once daily, 24 h after dosing, for the first four days of treatment, then on days 7, 14 and 30, at 8 a. m.
Animal experiments
Male Wistar rats, 30 days old, average weight 100 g, were kept on a normal laboratory diet with free access to drinking water. Experimentais and controls were selected at random. The former (N = 10) were injected intramuscularly once a day with l ml of an aqueous solution containing promazine (11.4 mg/ kg) and fluphenazine (0.8 mg/kg).
The latter (N = 10) received the same volume of 0.15 mol/1 aqueous NaCl (physiological saline). On each of days l, 2, and 7, appropriate numbers of animals from either group were anaesthetized (ether) and killed. Abdomina were opened immediately, blood was drained from the umbilical vein, centrifuged at once, and the serum stored frozen until enzyme activity determinations. Livers were removed, washed three times with ice-cold saline in order to remove blood, then individually homogenized in 0.14 mol/1 (50 g/l) aqueous KC1 with cooling (Ultra Turrax homogenizer, type TP 18-10 Janke and Kunkel GK) for l minute. Two ml portions of each homogenate were added 10 μΐ of aqueous Triton X-100 (200 g/l) and left 30 min at + 4 °C. The Triton-treated s well s untreated homogenates were centrifuged at 16000g for 1h at -h 4°C (refrigerated MSE 2L centrifuge), and the supernatants saved for enzyme activity determination. The Triton-treated samples showed the total, enzyme activities, while the untreated samples revealed the activities of unbound enzymes.
Results
The effect of drugs on enzyme activities in vitro was studied by using a serum pool to which the drugs had been added. No changes in enzyme activities were found.
Effects in humans
Up to the seventh day of treatment with promazine, serum aspartate aminotransferase activities in 60% of all patients slightly exceeded the average normal value ( fig. l a) . The corresponding percent ge in group II patients was somewhat lower. In the course of further treatment (all groups) the altered activity of aspartate aminotransferase mostly returned to normal. Serum alanine amiiiotransferase activities were apparently unaffected throughout, by either of the three treatments, except for very rare slight increases in group II patients ( fig. l b) . Raised serum y^gluta-myltransferase levels were initially observed in about 0.37 above the control value of group I and group II patients, and somewhat later in those of group III ( fig. l c) . At the completion of treatment, 50% of all patients had γ-glutamyltransferase activities above normal. The time course of the γ-glutamyltransferase activity increase was always regul r and uneventful.
Effects in rats
The first injection was followed by very marked increases in aspartate aminotransferase and alanine aminotransferase (1.4 and 0.7 above the control value), but not γ-glutamyltransferase activities. Thereafter the aspartate aminotransferase and alanine aminotransferase levels diminished gradually, but still remained above control values at completion of the treatment (day 7); a γ^glutamyltransfeΓase increase (0.5 above the eontrol* value, p < 0.05) was observed only on day 7 ( fig. 2) . The γ-glutamyl- transferase activity in the supernatant of the homogenate of the rat liver increased steadily throughout the treatment, whereas the activities f both alanine aminotransferase and aspartate aminotransferase increased for the first 3 days, but thereafter slowly decreased ( fig. 3) . With aspartate aminotransferase, the activities of total (unbound and bound) enzyme did not significantly change relative to that of unbound enzyme. In contrast, the activity of total γ-glutamyltransferase changed significantly. The largest increase in total liver γ-glutamyltransferase followed the first injection (0.58 above the control value), then stabilized at about 0.3 above the control value for the rest of the treatment (fig. 4) . The protein concentrations did not change significantly for the duration of an experiment. 
Discussion
The behaviour of serum enzyme activities in phenothiazine-treated patients (i. e. aspartate aminotransferase temporarily increased, alanine aminotransferase was mostly normal, and -glutamyltransferase increased occasionally) suggest that these drügs only slightly effect the serum transaminase activities at the customary dosage levels. The absence of marked changes in serum enzymatic activity levels at the completion of a 30 day treatment indicates that these drugs may altogether be considered äs non-toxic at moderate dosage levels. However, in critical phases of depression, elevated dösige levels and repeated dosing may be necessary. Such treatment should always be implemented with caution, and in particular, the use of phenothiazines at elevated dosage levels should be omitted in patients with manifest liver enlargement. Large doses of phenothiazines might cause cell damage. This assumption is confirmed by the outcome of our rat experiments. In the rat liver this effect resulted in a release of the intracellular enzymes, alanine aminotransferase, aspartate aminotransferase and -glutamyltransferase, into the extracellular space, and finally into blood plasma. The ceü damage following the immediate impact of the dtugs seems, however, to be stabilized subsequently, and even compensated for. As evidence of this, the serum activity either levels off with time ( -glutamyltransferase) or gradually reverts to normal, while the activities in liver homogeriates change less markedly but in the same wäy.
The argument for compensation of cell damage holds only 0 for the results observed with alanine aminotransferase and aspartate aminotransferase, btit obviously not for those with -glutamylt/ansferäse. The latter observations can, however, be explained if one re-members that γ-glutamyltransferase is partly localized on cell membranes. Therefore an additional mechanism of phenothiazine action must operate with regard to γ-glutamyltransferase. It is possible that these drugs induce de novo synthesis of this enzyme: γ-glutamyltransferase induction is a well known effect of drugs with various molecular structures (11, 12, 13) . Another possibility worth considering would be a membrane-solubilizing action whereby phenothiazine should cause a release of membranebound stibstances. A case in favour of this assumption has been reported for phenobarbitone (14, 15) .
